Amyloid-beta Polypeptide Vaccine


Disclosed are novel methods and compositions for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (Aβ). Immunization is preferably effected by administration of analogs of autologous APP or Aβ, said analogs being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Such methods and means include methods for the preparation of analogs and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Oct 28, 2014
  • Application: Dec 19, 2008
    US US 33984108 A
  • Priority: Dec 19, 2008
    US US 33984108 A
  • Priority: Aug 20, 2002
    US US 22380902 A
  • Priority: Apr 16, 2002
    DK DK PA200200558 A
  • Priority: Apr 16, 2002
    US US 37302702 P
  • Priority: Oct 22, 2001
    US US 33754301 P
  • Priority: Aug 20, 2001
    DK DK PA200101231 A

Download Citation

Sign in to the Lens